The inclusion criteria are as follows: (1) Pregnant women between 24 and 28 weeks of gestation, who were diagnosed with GDM through a routine 75 g of oral glucose tolerance test (OGTT) following the CMA diagnostic criteria if one or more values reached the following levels: fasting glucose ≥ 5.1 mmol/L, 1 h ≥ 10 mmol/L, and 2 h ≥ 8.5 mmol/L [13], (2) participants with singleton pregnancies, (3) patients treated with medical nutritional therapy, without insulin or other antidiabetic drugs, and (4) patients who signed an informed consent or whose guardian signed for them. The gene discussed is INS; the disease is gestational diabetes.